E. R. Squibb Sons, Inc.

Bristol-myers Squibb Compnay

Redpoint Bio Corporation

Atwal, Karnail

Grover, Gary J.

Kim, Kyoung S.

Karnail S Atwal

John E Lloyd

Saleem Ahmad

Heather J Finlay

Wayne D Vaccaro

George C Rovnyak

Francis N Ferrara

Gary J Grover

Michael A Poss

Kerry Leigh Spear

Shung C Wu

Michael F Gross

Charles Z Ding

Lin Yan

Philip D Stein

Rao S Bhandaru

Sundeep Dugar

David S Weinstein

Khehyong Ngu

Dinos P Santafianos

Steven V O'Neil

Joseph E Sundeen

David L Green

Kyoung S Kim

Spencer David Kimball

Bang-Chi Chen

David M Floyd

Robert Bryant

Annie J Pullockaran

Seshadri Neervannan

Jeffrey T North

Roy Kyle Palmer

Rok Cerne

John R McCullough

Syed Z Ahmed

Ivona Bakaj

Anita B Atwal, Legal Representative

Lawrnce G Hamann

Thomas J Caulfield

Joyce Chou

Gary James Grover

The present invention is directed to the use of a compound of Formula I and physiologically acceptable salts thereof wherein G, G, G, R, R, R, R, R, and Rare defined herein. Compounds according to Formula I can be used to enhance a sweet taste produced by a tastant. The invention is also directed to compositions comprising a compound according to the above formula. Other aspects of the invention provide methods, compounds, and compositions for improved food products wherein the food product comprises a compound according to Formula I and a reduced amount of a sweet tastant.

Heterocyclic compounds as sweetener enhancers

Novel heterocyclic dihydropyrimidine compounds useful as inhibitors of potassium channel function (especially inhibitors of the K1 subfamily of voltage gated Kchannels, especially inhibitors K1.5 which has been linked to the ultra-rapidly activating delayed rectifier Kcurrent I), methods of using such compounds in the prevention and treatment of arrhythmia and I-associated conditions, and pharmaceutical compositions containing such compounds.

Heterocyclic dihydropyrimidine compounds

Heterocyclic are provided which are sodium/proton exchange (NHE) inhibitors which have the structure wherein n is 1 to 5; X is N or C&#x2014;Rwherein Ris H, halo, alkenyl, alkynyl, alkoxy, alkyl, aryl or heteroaryl; Z is a heteroaryl group, R, R, Rand Rare as defined herein, and where X is N, Ris preferably aryl or heteroaryl, and are useful as antianginal and cardioprotective agents. In addition, a method is provided for preventing or treating angina pectoris, cardiac dysfunction, myocardial necrosis, and arrhythmia employing the above heterocyclic derivatives.

Heterocyclic sodium/proton exchange inhibitors and method

Compounds having the formula (I), and pharmaceutically acceptable salts thereof,are useful for modulating mitochondrial FFATPase activity and treating ischemic conditions including myocardial infarction, congestive heart failure, and cardiac arrhythmias.

(1-phenyl-2-heteoaryl)ethyl-guanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolase

Heterocyclic are provided which are sodium/proton exchange (NHE) inhibitors which have the structurewherein n is 1 to 5; X is N or C&#x2014;Rwherein Ris H, halo, alkenyl, alkynyl, alkoxy, alkyl, aryl or heteroaryl; Z is a heteroaryl gorup, R, R, Rand Rare as defined herein, and where X is N. Ris preferably aryl or heteroaryl, and are useful as antianginal and cardioprotective agents. In addition, a method is provided for preventing or treating angina pectoris, cardiac dysfunction, myocardial necrosis, and arrhythmia employing the above heterocyclic derivatives.

Indanes, benzopyrans and analogues thereof are potassium channel inhibitors and blockers of IKur and have the structure:where A, B, D, Q, X, R, R, Xand Rare as defined herein. These compounds are useful as antiarrhythmic agents. In addition, a method is provided for preventing cardiac arrhythmia employing the above compounds.

Potassium channel inhibitors and method

Novel heterocyclic dihydropyrimidine compounds useful as inhibitors of potassium channel function (especially inhibitors of the K 1 subfamily of voltage gated K channels, especially inhibitors K 1.5 which has been linked to the ultra-rapidly activating delayed rectifier K current I ), methods of using such compounds in the prevention and treatment of arrhythmia and I -associated conditions, and pharmaceutical compositions containing such compounds.

Lactam derivatives as antiarrhythmic agents

Benzoic acid derivatives and related compounds as antiarrhythmic agents

The (R)-enantiomer of 4-&lsqb;&lsqb;(cyanoimino)&lsqb;(1,2,2-trimethylpropyl)amino&rsqb;methyl&rsqb;amino&rsqb;benzonitrile as well as the corresponding (S)-enantiomer are useful for promoting hair growth such as in male pattern baldness.

Enantiomers of 4-&lsqb;&lsqb;(cyanoimino) &lsqb;(1,2,2-trimethylpropyl)amino&rsqb;methyl&rsqb;amino&rsqb;benzonitrile

A method for inhibiting hair loss and/or promoting hair growth in chemotherapy and/or radiation therapy patients wherein the (R)-enantiomer of 4-&lsqb;&lsqb;(cyanoimino)-&lsqb;(1,2,2-trimethylpropyl)amino&rsqb;methyl&rsqb;amino&rsqb;benzonitrile is administered prior to, simultaneous with and/or after chemotherapy and/or radiation treatment.

Method of inhibiting or treating chemotherapy-induced hair loss

The (R)-enantiomer of 4-&lsqb;&lsqb;(cyanoimino)-&lsqb;(1,2,2-trimethylpropyl)amino&rsqb;methyl&rsqb;amino&rsqb;-benzonitrile as well as the corresponding (S)-enantiomer are useful for promoting hair growth such as in male pattern baldness.

Growing community of inventors

Newtown, PA, United States of America

Karnail S Atwal